Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

about

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

Item

http://www.wikidata.org/entity/Q42710884

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

@en

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

@nl

type

Item

label

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

@en

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

@nl

prefLabel

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

@en

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

@nl

P1476

Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.

@en

P2093

Kate J Newberry

http://www.w3.org/2001/XMLSchema#string

Liang Zhang

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

P2860

The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils

CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells

The B cell antigen receptor and overexpression of MYC can cooperate in the genesis of B cell lymphomas

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.

Chemokines and cell migration in secondary lymphoid organs.

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Regulation of dendritic cell maturation and function by Bruton's tyrosine kinase via IL-10 and Stat3.

Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response

Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells.

P304

495-497

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1586/ECI.13.31

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23730878

http://www.w3.org/2001/XMLSchema#string